Muscular Dystrophy - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 139
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M0633E79524EN
Leaflet:

Download PDF Leaflet

Muscular Dystrophy - Pipeline Review, H2 2017
Muscular Dystrophy - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 1, 27 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Muscular Dystrophy - Overview
Muscular Dystrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Muscular Dystrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscular Dystrophy - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Achelios Therapeutics Inc
AMO Pharma Ltd
aTyr Pharma Inc
Benitec Biopharma Ltd
Bio Blast Pharma Ltd
Biophytis SAS
Corcept Therapeutics Inc
Evotec AG
Fulcrum Therapeutics Inc
Genethon SA
Ionis Pharmaceuticals Inc
Marina Biotech Inc
Medestea Research & Production SpA
Novogen Ltd
Pfizer Inc
Prothelia Inc
Recursion Pharmaceuticals Inc
SanBio Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
Strykagen Corp
Takeda Pharmaceutical Co Ltd
Ultragenyx Pharmaceutical Inc
WAVE Life Sciences Ltd
Muscular Dystrophy - Drug Profiles
ACE-083 - Drug Profile
Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit DUX4 for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile
ATYR-1940 - Drug Profile
AVGN-7 - Drug Profile
baliforsen - Drug Profile
BB-301 - Drug Profile
BIO-103 - Drug Profile
domagrozumab - Drug Profile
Fusion Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile
Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile
Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile
IUCT-169 - Drug Profile
IUCT-290 - Drug Profile
IUCT-309 - Drug Profile
ketoprofen - Drug Profile
LR-08 - Drug Profile
mexiletine hydrochloride - Drug Profile
MYO-101 - Drug Profile
MYO-102 - Drug Profile
MYO-103 - Drug Profile
MYO-201 - Drug Profile
MYO-301 - Drug Profile
Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy Type 1 - Drug Profile
Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Type 1 - Drug Profile
omigapil - Drug Profile
poloxamer - Drug Profile
PRT-01 - Drug Profile
RNAi Gene Therapy to Inhibit Myotilin for LGMD - Drug Profile
RP-33 - Drug Profile
SB-308 - Drug Profile
SIWA-318 - Drug Profile
Small Molecule to Inhibit DUX4 for Muscular Dystrophy - Drug Profile
Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile
Small Molecule to Target RNA for Myotonic Dystrophy Type 1 - Drug Profile
Small Molecules for Dysferlinopathies - Drug Profile
Small Molecules for Emery-Dreifuss Muscular Dystrophy - Drug Profile
Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile
Small Molecules for Merosin-Deficient Congenital Muscular Dystrophy Type 1A - Drug Profile
Small Molecules for Myotonic Dystrophy - Drug Profile
Small Molecules for Pain - Drug Profile
Small Molecules for Walker-Warburg syndrome - Drug Profile
Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy - Drug Profile
Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy - Drug Profile
Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile
Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile
Stem Cell Therapy for Muscular Dystrophy - Drug Profile
Stem Cell Therapy to Activate ZSCAN4 for Muscular Dystrophy - Drug Profile
Stryka-232 - Drug Profile
Stryka-234 - Drug Profile
Stryka-425 - Drug Profile
Stryka-533 - Drug Profile
Stryka-978 - Drug Profile
tideglusib - Drug Profile
trehalose - Drug Profile
TXA-127 - Drug Profile
VAL-0411 - Drug Profile
WITH-1101 - Drug Profile
XN-001 - Drug Profile
Muscular Dystrophy - Dormant Projects
Muscular Dystrophy - Discontinued Products
Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Muscular Dystrophy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H2 2017
Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H2 2017
Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H2 2017
Muscular Dystrophy - Pipeline by aTyr Pharma Inc, H2 2017
Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H2 2017
Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd, H2 2017
Muscular Dystrophy - Pipeline by Biophytis SAS, H2 2017
Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H2 2017
Muscular Dystrophy - Pipeline by Evotec AG, H2 2017
Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H2 2017
Muscular Dystrophy - Pipeline by Genethon SA, H2 2017
Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Muscular Dystrophy - Pipeline by Marina Biotech Inc, H2 2017
Muscular Dystrophy - Pipeline by Medestea Research & Production SpA, H2 2017
Muscular Dystrophy - Pipeline by Novogen Ltd, H2 2017
Muscular Dystrophy - Pipeline by Pfizer Inc, H2 2017
Muscular Dystrophy - Pipeline by Prothelia Inc, H2 2017
Muscular Dystrophy - Pipeline by Recursion Pharmaceuticals Inc, H2 2017
Muscular Dystrophy - Pipeline by SanBio Inc, H2 2017
Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2017
Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H2 2017
Muscular Dystrophy - Pipeline by Strykagen Corp, H2 2017
Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2017
Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H2 2017
Muscular Dystrophy - Dormant Projects, H2 2017
Muscular Dystrophy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Muscular Dystrophy - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Muscular Dystrophy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Acceleron Pharma Inc
Achelios Therapeutics Inc
AMO Pharma Ltd
aTyr Pharma Inc
Benitec Biopharma Ltd
Bio Blast Pharma Ltd
Biophytis SAS
Corcept Therapeutics Inc
Evotec AG
Fulcrum Therapeutics Inc
Genethon SA
Ionis Pharmaceuticals Inc
Marina Biotech Inc
Medestea Research & Production SpA
Novogen Ltd
Pfizer Inc
Prothelia Inc
Recursion Pharmaceuticals Inc
SanBio Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
Strykagen Corp
Takeda Pharmaceutical Co Ltd
Ultragenyx Pharmaceutical Inc
WAVE Life Sciences Ltd
Skip to top


Duchenne Muscular Dystrophy - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 296 pages

Ask Your Question

Muscular Dystrophy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: